Analyzing iCo Therapeutics (OTCMKTS:ICOTF) & Clearside Biomedical (CLSD)
iCo Therapeutics (OTCMKTS:ICOTF) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
This table compares iCo Therapeutics and Clearside Biomedical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares iCo Therapeutics and Clearside Biomedical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Clearside Biomedical||$30,000.00||1,515.80||-$58.97 million||($2.69)||-0.53|
iCo Therapeutics has higher earnings, but lower revenue than Clearside Biomedical.
Volatility and Risk
iCo Therapeutics has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500.
Institutional and Insider Ownership
39.9% of Clearside Biomedical shares are held by institutional investors. 15.4% of Clearside Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of current recommendations for iCo Therapeutics and Clearside Biomedical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Clearside Biomedical has a consensus target price of $11.83, suggesting a potential upside of 733.33%. Given Clearside Biomedical’s higher probable upside, analysts clearly believe Clearside Biomedical is more favorable than iCo Therapeutics.
Clearside Biomedical beats iCo Therapeutics on 7 of the 9 factors compared between the two stocks.
About iCo Therapeutics
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.
About Clearside Biomedical
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Receive News & Ratings for iCo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iCo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
You may be interested
Bitcoin, Ethereum, Ripple, Bitcoin Cash, Litecoin, EOS, Binance Coin, Stellar, Cardano, TRON: Price Analysis April 29 – CointelegraphEditor - April 29, 2019
[ad_1] Bitcoin, Ethereum, Ripple, Bitcoin Cash, Litecoin, EOS, Binance Coin, Stellar, Cardano, TRON: Price Analysis April 29 CointelegraphPrice Analysis. The views…
(BTC) Bitcoin Price Prediction 2019 / 2020 / 5 years (Updated 04/29/2019): BTC/USD Rises From Support – BeInCryptoEditor - April 29, 2019
[ad_1] (BTC) Bitcoin Price Prediction 2019 / 2020 / 5 years (Updated 04/29/2019): BTC/USD Rises From Support BeInCryptoHow will Bitcoin (BTC)…
Litecoin (LTC) price analysis: LTC/USD hovers below $70.00, more sell-off is possible – FXStreetEditor - April 29, 2019
[ad_1] Litecoin (LTC) price analysis: LTC/USD hovers below $70.00, more sell-off is possible FXStreetLitecoin (LTC) peaked at $99.47 on April 3…